Avastin Sales Data
| Rank 17 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Avastin U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 17 ( 1) |
$650,208 | -1.25% | 455 | 0.22% |
| Q3 2013 | 16 | $658,457 | -1.41% | 454 | -4.22% |
| Q2 2013 | 16 | $667,885 | 4.22% | 474 | 2.60% |
| Q1 2013 | 16 | $640,823 | 1.04% | 462 | n/a |
| Q4 2012 | 16 | $634,201 | -2.49% | 462 | -2.12% |
| Q3 2012 | 16 ( 2) |
$650,363 | 0.41% | 472 | -0.84% |
| Q2 2012 | 18 (2) |
$647,721 | 2.46% | 476 | 3.48% |
| Q1 2012 | 20 (1) |
$632,183 | -1.92% | 460 | -2.13% |
| Q4 2011 | 21 | $644,570 | 2.86% | 470 | 3.52% |
| Q3 2011 | 21 | $626,618 | -3.57% | 454 | -3.61% |
| Q2 2011 | 21 | $649,802 | -1.29% | 471 | -0.63% |
| Q1 2011 | 21 | $658,284 | n/a | 474 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
Related news
| Date | Article |
|---|---|
| December 7, 2022 | Drug Choice Might Matter for Patients With Macular Degeneration |
| July 15, 2022 | 'Stepped' Approach to Treating Diabetic Eye Disease May Be Best |
